Inogen Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $116.17, for a total value of $290,425.00. Following the transaction, the executive vice president now directly owns 7,297 shares of the company’s stock, valued at $847,692.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Matt Scribner also recently made the following trade(s):

  • On Thursday, December 14th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $120.34, for a total value of $300,850.00.
  • On Monday, November 13th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $112.35, for a total value of $280,875.00.

Inogen Inc (NASDAQ:INGN) traded down $0.96 on Thursday, reaching $114.99. The company had a trading volume of 98,767 shares, compared to its average volume of 174,217. Inogen Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05. The company has a market capitalization of $2,400.00, a price-to-earnings ratio of 80.41, a PEG ratio of 3.94 and a beta of 1.13.

Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. During the same quarter in the prior year, the company posted $0.25 earnings per share. Inogen’s revenue was up 26.8% on a year-over-year basis. equities analysts forecast that Inogen Inc will post 1.19 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INGN. Schroder Investment Management Group bought a new stake in Inogen during the second quarter worth about $132,000. Ameritas Investment Partners Inc. raised its holdings in Inogen by 6.1% during the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 86 shares in the last quarter. Simplex Trading LLC bought a new stake in Inogen during the fourth quarter worth about $153,000. Victory Capital Management Inc. raised its holdings in Inogen by 17.8% during the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after acquiring an additional 307 shares in the last quarter. Finally, Pinebridge Investments L.P. raised its holdings in Inogen by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock worth $204,000 after acquiring an additional 33 shares in the last quarter.

Several research analysts have recently weighed in on INGN shares. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective for the company in a research report on Thursday, November 9th. Needham & Company LLC upped their price objective on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. Leerink Swann reaffirmed an “outperform” rating and set a $120.00 price objective (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Finally, BidaskClub cut Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Inogen presently has a consensus rating of “Hold” and a consensus target price of $102.71.

TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/18/insider-selling-inogen-inc-ingn-evp-sells-2500-shares-of-stock.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.